Therapy Detail

Therapy Name TAK-960
Therapy Description

TAK-960 is an inhibitor of PLK1, which may result in cell growth inhibition and a reduction in tumor size (PMID: 22188812).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
TAK-960 PLK1 Inhibitor 17 TAK-960 is an inhibitor of PLK1, which may result in cell growth inhibition and a reduction in tumor size (PMID: 22188812).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown breast cancer not applicable TAK-960 Preclinical - Cell line xenograft Actionable In a preclinical study, breast cancer cells treated with TAK-960 demonstrated a decrease in tumor size in cell line xenograft models (PMID: 22188812). 22188812
Unknown unknown colorectal cancer not applicable TAK-960 Preclinical - Cell line xenograft Actionable In a preclinical study, colorectal cancer cells treated with TAK-960 demonstrated cell growth inhibition and decreased tumor size in both culture and cell line xenograft models (PMID: 22188812). 22188812
Unknown unknown prostate cancer not applicable TAK-960 Preclinical - Cell line xenograft Actionable In a preclinical study, prostate cancer cells treated with TAK-960 demonstrated a decrease in tumor size in cell line xenograft models (PMID: 22188812). 22188812
Unknown unknown ovarian cancer not applicable TAK-960 Preclinical - Cell line xenograft Actionable In a preclinical study, ovarian cancer cells treated with TAK-960 demonstrated cell growth inhibition and decreased tumor size in both culture and cell line xenograft models (PMID: 22188812). 22188812
Unknown unknown lung cancer not applicable TAK-960 Preclinical - Cell line xenograft Actionable In a preclinical study, lung cancer cells treated with TAK-960 demonstrated a decrease in tumor size in cell line xenograft models (PMID: 22188812). 22188812
Unknown unknown leukemia not applicable TAK-960 Preclinical - Cell line xenograft Actionable In a preclinical study, colorectal cancer cells treated with TAK-960 demonstrated cell growth inhibition, decreased tumor size, and increased median survival in both culture and cell line xenograft models (PMID: 22188812). 22188812
Clinical Trial Phase Therapies Title Recruitment Status